Adjuvant Cisplatin

DRUG3 trials

Sponsors

Radiation Therapy Oncology Group, Xiwei XU, Ming-Yuan Chen

Conditions

Bladder CancerLocally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

CompletedNCT00777491

Radiation Therapy Oncology GroupBladder Cancer

Start: 2008-12-31End: 2022-05-20Updated: 2022-06-15

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

RecruitingNCT07371234

Xiwei XULocally Advanced Head and Neck Squamous Cell Carcinoma

Start: 2025-12-15End: 2028-12-30Target: 22Updated: 2026-02-03

Phase 3

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

RecruitingNCT07524452

Ming-Yuan ChenLocally Advanced Head and Neck Squamous Cell Carcinoma

Start: 2026-02-06End: 2032-02-28Target: 430Updated: 2026-04-13

Related Papers

Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial.

Journal of Clinical Oncology2018-02-20